Microvascular decompression may cause hearing loss, facial numbness or weakness, double vision, balance problems, cerebellar or brainstem injury, cerebrospinal fluid leakage, meningitis, wound infection, bleeding, stroke, seizures, anesthesia-related complications, persistence of pain, or recurrence after an initially successful result
Recheck at 48-72 hours
This protocol activated TrkB, AKT, and ERK signaling in vivo
It achieves this by selectively binding to adipose tissue and upregulating specific receptors involved in fat metabolism, without the systemic growth-promoting effects that might impact other tissues